Stop the Stock-outs! Access to Essential Medicines for All Christa Cepuch BSc Phm Health Action International Africa RHS Coalition Meeting 27 May 2010,

Slides:



Advertisements
Similar presentations
1 Policy options to address access to chronic disease medicines Dr. Richard Laing Ms. Alexandra Cameron Department of Essential Medicines and Pharmaceutical.
Advertisements

1 MDG Target 8.E gap analysis Dr Hans Hogerzeil Director, Department of Essential Medicines and Pharmaceutical Policies, World Health Organization October.
World Health Organization
Overview of the Global Fund: Guiding Principles Grant Cycle / Processes & Role of Public Private Partnerships Johannesburg, South Africa Tatjana Peterson,
MEDICINES SELECTION & FORMULARY MANAGEMENT
A REPRODUCTIVE HEALTH COMMODITY SECURITY STRATEGY FOR THE WEST AFRICA SUBREGION 2007 – 2011 Dr. Kabba Joiner, WAHO 2006 Fall Meeting of the Reproductive.
Presented to CSO workshops in Kabwe on 18 July 2014, Livingstone on 28 July 2014 and Lusaka on 27 August 2014.
Energising & Empowering Civil Society Engagement with Public Budgets and Expenditure in Southern Africa Centre for Economic Governance and AIDS in Africa.
Medicines Transparency Alliance (MeTA) Presented to CSO workshops during 2013 in SOLWEZI AUGUST 27 NDOLA AUGUST 29 LUSAKA OCTOBER 22.
Stockouts: The legal framework Sasha Stevenson 25 July 2013.
Elizabeth Lule Manager ACTafrica The World Bank’s Support to HIV/AIDS Programs in Africa.
Country Ownership for Reproductive Health; An NGO perspectiveSLIDE 1 “ACCESS FOR ALL: SUPPLYING A NEW DECADE FOR REPRODUCTIVE HEALTH ” Country Ownership.
International Experience in Pharmaceutical Services for Promoting Access to Medicines: Canada, Cuba, England, Mexico International Seminar on the Challenges.
From choice, a world of possibilities IPPF/WHR – UNFPA/DC USAID Graduation Policy Fact-finding Trip Peru – May 16-22, 2010.
Supply Chains Management for Pharmacy
Active Pharmaceutical Management Strategies of Health Insurance Systems to Improve Cost-Effective Use of Medicines in Low- and Middle-Income Countries:
Access to HIV/AIDS, Tuberculosis and Malaria Medicines. WHO/UNICEF Technical Briefing Seminar on Essential Medicines Policies. Geneva, 18 – 22 September.
PRESENTATION TO THE MOLE CONFERENCE, CHANCES HOTEL, 15 JULY 2009 YIGA BAKER M ANEW REGIONAL COORDINATOR EASTERN AFRICA.
Abstract 213 ICIUM: Antalya, Turkey. November 14-18, 2011.
Moving towards the goal of Universal Health Coverage (UHC) in Bangladesh Md. Ashadul Islam Director General Health Economics Unit Ministry of Health and.
How can global funders support and strengthen local community responses to HIV? Reflections from a recent three-country study on “Aid for AIDS” Jerker.
1 New Funding Model Key features and implementation Inter-Agency Meeting 5-7 March 2014 Linda Mafu, Head Political and Civil Society Advocacy Department,
Generating evidence for change: Implementing the post-ICIUM research agenda Dennis Ross-Degnan, ScD Harvard Medical School and Harvard Pilgrim Health Care.
National Medicine Policy
BSP Contraceptive Initiative To broaden sustainable access to quality hormonal contraceptives through a new commercial venture Reproductive Health Supplies.
How to determine medicines benefits policy and program needs?
Wilbert Bannenberg SARPAM
Medicines Transparency Alliance01/10/2015 Availability of Medicines Anita Wagner Harvard Medical School & WHO Collaborating Center in Pharmaceutical Policy.
September 2009 Guide to Producing Campaign to End Pediatric Aids (CEPA) National Advocacy Action Plans (NAAPs)
1 Stop Stock-outs! Access to Medicines for All! anti-counterfeiting initiatives and other access barriers Christa Cepuch OSI AEM Initiative – CS Role and.
Country Assessment to Determine Factors Influencing the Cost, Availability and Distribution of Acyclovir in Eight Sub-Saharan African Countries Catherine.
Tanzania1. 2 Tanzania Assessment Gabriel Upunda Tanzania3 DemographicsTanzania Area (sq km)945,100 Population 32,900,000 25% urban GNP per capitaUS $240.
Stop the Stock-outs! Civil Society approaches to monitoring PSM for essential medicines Christa Cepuch BSc Phm Health Action International (HAI) Africa.
8 TH -11 TH NOVEMBER, 2010 UN Complex, Nairobi, Kenya MEETING OUTCOMES David Smith, Manager PEI Africa.
Forging Partnerships at Country Level to Achieve Contraceptive Security: Reproductive Health Supplies in Six Countries Elizabeth Leahy Madsen and Karen.
Lucile de Comarmond Chief Pharmacist Workshop on Impact of TRIPS/IP on Access to Medicine September 2014.
MALAWI GOVERNMENT MINISTRY OF HEALTH PROGRESS ON GOOD GOVERNANCE IN THE PHARMACEUTICAL SECTOR IN MALAWI By Dr Charles Mwansambo Secretary for Health 20.
Maternal Health Supplies in Bangladesh and Uganda Reproductive Health Supplies Coalition 28 May 2010 Elizabeth Leahy Madsen Jennifer Bergeson-Lockwood.
Health challenges in an enlarged Europe Report from Parallel Session A1 Dr. Natasha Azzopardi Muscat Ministry of Health - Malta.
Ministry for Women, Youth, Children and Persons with Disabilities.
Availability of children’s medicines in Africa, 2007 Jane Robertson, Gilles Forte, Suzanne Hill.
Bad intentions - good policies: Who wins? Case exercise and role play on drug counterfeiting in an LDC context World Bank Case Exercise – all names and.
Yemaneberhan Taddesse.  PASDEP(plan of accelerated and sustainable development for the Eradication of poverty) Poverty reduction strategy is the main.
A BASELINE SURVEY OF THE PHARMACEUTICAL SECTOR IN TANZANIA
WHO/OMS Improving and increasing investments in the health outcomes of the poor Macroeconomics and Health in context Dr. Sergio Spinaci, WHO Senegal, February.
WHO-Technical Briefing Seminar | October-November 2012 Dr Cécile Macé 1 |1 | Good Governance for Medicines Programme Dr Cécile Macé EMP/MPC.
Addressing Financial Needs. What is the best investment we can make for India ’ s future? “ The development of children is the first priority on the country.
COMPARATIVE ANALYSIS OF SELECTED ESSENTIAL DRUG LISTS AZIZ JAFAROV/RICHARD LAING.
Quantification of Antimalarials PSM Workshop Nairobi, Kenya February 21, 2006.
Zokufa HZ, Pillay T Pharmaceutical Policy and Planning National Department of Health- South Africa.
TBS 2008-H. Tata & M. Babaley Mapping and In-depth Assessment of Medicines Procurement and Supply Systems WHO Technical Briefing Seminar 17 th -21 st November.
High Level Policy Dialogue – Cambodia Towards a Strong and Sustainable Health Sector Development ( Health Strategic Plan) 24 June, 2015 Cambodia.
MONITORING MEDICINE AVAILABILITY AND PRICES IN UGANDA By Denis Kibira HEPS Uganda.
Selection of essential medicines Richard Laing and Deidre Dimancesco TBS 2011 Department of Essential Medicines & Pharmaceutical Policies TBS 2008.
Multi-country study on drug supply and distribution activities of faith-based supply organizations in sub-Saharan African countries, 2003 Sophie Logez.
Rational Selection of Essential Medicines Tim Reed World health Assembly May 2014.
Stop Stock-outs Campaign: Uganda Kibira Denis (MPS) HEPS-UGANDA 27 th May 2010.
Ministry’s Vision for Universal Health Coverage Dr San San Aye Director (Planning) Department of Health Planning Ministry of Health National Dialogue on.
CONTRACT MONITORING COALITIONS: LOWERING PROCUREMENT RISKS Robert Hunja, WBI.
ADDRESSING PHARMACEUTICAL SUPPLY CHAIN NEEDS PRESENTATION TO HEALTH DONOR GROUP MEETING 8 July 2009.
UHC 2030 CSO engagement mechanism Bruno Rivalan IHP+ Northern CSO Representative IHP+ Steering committee 21 th June 2016.
Engaging CSOs in UHC 2030 Bruno Rivalan IHP+ Northern CSO Representative IHP+ Steering committee 21 th June 2016.
Financing Heath Care in Low Income Coutnries
IMPACT OF DRUG POLICY ON IMPROVING ACCESS TO MEDICINES IN DELHI
Richard Laing EMP/WHO TBS 2012
East Central and Southern Africa Health Community (ECSA HC)
Health Technology Assessment for Universal Health Coverage
Health system assessments
Stop Stock-outs Campaign in Uganda
Richard Laing WHO/PAU TBS 2013
Presentation transcript:

Stop the Stock-outs! Access to Essential Medicines for All Christa Cepuch BSc Phm Health Action International Africa RHS Coalition Meeting 27 May 2010, Kampala

What are Essential Medicines?  satisfy the priority health care needs of the population  selected with due regard to public health relevance, evidence on efficacy and safety, and comparative cost- effectiveness  intended to be available within the context of functioning health systems at all times in adequate amounts, in the appropriate dosage forms, with assured quality and adequate information, and at a price the individual and the community can afford  implementation of the concept of essential medicines is intended to be flexible  exactly which medicines are regarded as essential remains a national responsibility

WHO: Availability of essential medicines Average availability was only 34.9% in the public sector and 63.2% in the private sector. Public sector availability of medicines is consistently lower than in the private sector.

Country-specific evidence: Kenya MMePA (monitoring of medicine prices and availability)

Barriers to Access  Health system capacity  Health budgets  Lack of research and development  Price  Patents  Quality of diagnosis  Accurate prescribing  Selection, distribution, dispensing of medicines  Medicine quality

WHO: Public expenditure on medicines There is wide variation in national per capita spending on medicines by the public sector, ranging from US $0.04 to $ among developing countries.

Availability of Artemether/lumefantrine 20/120 mg in Kenya Global Fund grant start date (02/2006) WHO / HAI Africa: Increased finances and differential pricing -- impact on availability

Using evidence for advocacy: Stop Stock-outs (SSO)!  Work with partners in different countries to engage the public on their Human Right to access essential medicines  KETAM, CIN, EPN, KEHPCA, AGHA, NAPHOFANU, HEPS, ZLP+, TLAC, MHEN, others

SSO campaign: context and structure  30 years after the introduction of the EM concept, there are simply not enough medicines on the pharmacy shelves.  Stock-outs are worst in rural areas, and harm poor people.  Stock-outs force people to purchase medicines from much higher suppliers in the private sector or -- more frequently -- simply to go without needed medicines.  The failure to properly stock public health pharmacies and clinics stems in part from economic constraints and bureaucratic obstacles. But above all, it is a failure of political will. If governments commit to get EMs on the shelves, they can do it.  CS teams in five countries (Malawi, Ke, Ug, Zam, Zim)  CS teams getting small grants to run their campaigns  Truly a networking effort

SSO campaign: demands The SSO campaign is calling on governments and health departments to end stock-outs now by: Giving financial and operational autonomy to the national medicines procurement and supply agency Allowing representation of civil society on the board of the national medicines procurement and supply agency Ending corruption in the medicine supply chain to stop theft and diversion of essential medicines (EMs) Providing a dedicated budget line for EMs Living up to commitments to spend 15% of national budgets on health care Providing EMs for free at all public health institutions

SSO continental campaign  Taking SSO issues to the regional and sub-regional levels (WHO AFRO, AU, EAC, SADC, etc)  Getting broad continental support for the UNITAID Patent Pool  Countering problematic counterfeit legislation  Highlighting specific medicines (CEPA, RH medicines …?)